List of Excipients in Branded Drug ORENITRAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
United Therapeutics Corporation	ORENITRAM	treprostinil	66302-300	ALCOHOL	2028-12-15
United Therapeutics Corporation	ORENITRAM	treprostinil	66302-300	BUTYL ALCOHOL	2028-12-15
United Therapeutics Corporation	ORENITRAM	treprostinil	66302-300	CELLULOSE ACETATE	2028-12-15

ORENITRAM Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 1, 2026

Orenitram is United Therapeutics' oral extended-release treprostinil product for pulmonary arterial hypertension. Its commercial formulation uses a conventional hydrophilic matrix-tablet platform built around hypromellose, with lactose, colloidal silicon dioxide, and magnesium stearate supporting manufacturability. The principal commercial opportunity is not a simple excipient substitution. It is development of an equivalent extended-release profile, supported by a robust dissolution method, pharmacokinetic evidence, and a patent strategy that avoids protected formulation claims.

What is Orenitram and how does its formulation work?

Orenitram contains treprostinil diolamine, a prostacyclin analogue administered orally as an extended-release tablet. The FDA approved Orenitram on December 20, 2013, for reducing disease progression and hospitalization risk in adults with pulmonary arterial hypertension, WHO Group 1 [1].

The product is supplied in multiple strengths, including 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2.5 mg, and 5 mg tablets. Multiple strengths support titration and chronic dosing while reducing the need for tablet splitting. The label instructs patients to take Orenitram with food and swallow tablets whole [1].

The formulation strategy has three commercial objectives:

1. Maintain sustained treprostinil release over the dosing interval.
2. Support dose escalation using multiple tablet strengths.
3. Avoid the infusion-site complications associated with parenteral prostacyclin delivery.

Orenitram is a small-molecule drug, not a biologic. Biosimilar legislation therefore does not apply. Any competitive product would generally proceed through an ANDA, a 505(b)(2) application, or a non-U.S. equivalent pathway.

What excipients are used in Orenitram tablets?

The FDA labeling identifies lactose monohydrate, hypromellose, magnesium stearate, and colloidal silicon dioxide as inactive ingredients in Orenitram tablets [1].

Excipient	Likely formulation role	Commercial relevance
Hypromellose	Hydrophilic matrix former and release-control polymer	Central to extended-release performance and dissolution matching
Lactose monohydrate	Diluent and tablet-mass builder	Supports compression and dose uniformity at low treprostinil loading
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Supports ejection and reduces tooling adhesion
Film-coating components	Protection, appearance, identification, and swallowability	Enables strength differentiation and handling control

The public label does not disclose quantitative excipient levels, polymer viscosity grade, particle-size distribution, granulation conditions, or compression force. Those variables can materially affect release kinetics and are likely to be important in any generic or reformulation program.

Why is hypromellose important?

Hypromellose is the key excipient platform in the public formulation description. In contact with gastrointestinal fluid, the polymer hydrates and forms a gel layer. Treprostinil release then depends on a combination of diffusion, matrix erosion, drug loading, tablet geometry, polymer grade, and compression conditions.

For a low-dose drug such as treprostinil, the developer must control blend uniformity across the strength range. Small changes in API distribution or matrix density can cause disproportionate changes in early release. The commercial value of hypromellose expertise therefore lies in process control, not merely in supplying a commodity polymer.

What formulation risks arise from lactose and magnesium stearate?

Lactose can affect compactability, porosity, moisture behavior, and blend segregation. Magnesium stearate can reduce wetting and slow dissolution when over-lubrication occurs. These effects matter in an extended-release matrix because tablet hardness and hydrophobic lubricant coverage can change the hydration rate of hypromellose.

Excipient suppliers with controlled grades, technical documentation, and experience supporting modified-release ANDAs have a stronger position than suppliers offering only low-cost material.

What patents protect Orenitram?

Orenitram's protection is based on a combination of formulation, dosage-form, method-of-use, and regulatory exclusivity rights. The relevant patent estate should be assessed through the FDA Orange Book, United Therapeutics' public filings, and the underlying U.S. patent families [2, 3].

The most important protection categories are:

Protection category	Relevance to Orenitram
Extended-release treprostinil formulation claims	May cover matrix composition, release profile, or dosage form
Treprostinil oral-use claims	May cover treatment of pulmonary arterial hypertension using oral treprostinil
Tablet manufacturing claims	May cover granulation, compression, coating, or controlled release
Strength and dosing claims	May affect product labeling and titration strategies
FDA regulatory exclusivity	Can delay ANDA approval independently of patent expiry

United Therapeutics has publicly disclosed patent protection for Orenitram and other treprostinil products in its SEC filings. Patent expiration dates depend on the specific patent, patent-term adjustment, patent-term extension, terminal disclaimers, and Orange Book listing status [3].

How should the Orenitram patent estate be analyzed?

A serious freedom-to-operate review should separate three questions:

1. Does a patent claim the same extended-release matrix or release profile?
2. Does a patent claim the same oral treprostinil indication or dosing regimen?
3. Is the patent listed for Orenitram in the Orange Book, or is it enforceable only through ordinary patent litigation?

A formulation patent can create a larger practical barrier than the expiration of an older composition-of-matter patent. A generic applicant may avoid one claim by changing the polymer system, but a broad method-of-use claim may still create litigation exposure if the proposed label encourages the patented use.

When did Orenitram lose exclusivity?

Orenitram received five-year new chemical entity exclusivity because it was the first FDA-approved product containing treprostinil in an oral extended-release dosage form. The approval date was December 20, 2013, placing the basic NCE exclusivity period in December 2018, subject to FDA regulatory calculations [1, 4].

NCE exclusivity is separate from patent protection. Its end did not eliminate formulation or method-of-use barriers. An ANDA applicant could submit a Paragraph IV certification against listed patents once permitted by the Hatch-Waxman framework, but approval and commercial launch would still depend on patent litigation, settlement terms, and the outcome of any 30-month stay.

What is the Orange Book status of Orenitram?

The FDA Orange Book is the controlling source for listed Orenitram patents and exclusivity codes. Orange Book listings can change as patents are added, delisted, corrected, or challenged [2].

For commercial diligence, the relevant data fields are:

• NDA number and product strength.
• Patent number and expiration date.
• Patent use code.
• Exclusivity code and expiration.
• Whether the patent is listed against all strengths or only specific dosage forms.
• Whether an applicant has submitted a Paragraph IV certification.
• Whether litigation triggered a statutory approval stay.

A patent expiration date in the Orange Book is not necessarily the earliest possible generic launch date. A launch may occur before expiry under a settlement, after a successful validity or non-infringement decision, or at risk if the applicant accepts litigation exposure.

Which companies are challenging Orenitram?

Publicly available sources should be reviewed for Paragraph IV notices, ANDA litigation complaints, district court rulings, and settlement agreements involving United Therapeutics and proposed Orenitram competitors.

The competitive set is likely to include:

• Generic pharmaceutical manufacturers with modified-release tablet capabilities.
• 505(b)(2) developers pursuing a different oral treprostinil delivery system.
• Specialty pulmonary hypertension companies developing oral prostacyclin-pathway products.
• Developers of inhaled or parenteral treprostinil products that compete for the same treatment population.

A generic challenge would probably focus on the extended-release tablet claims, while a 505(b)(2) program could seek differentiation through a capsule, multiparticulate system, osmotic platform, or alternative release technology.

No biosimilar challenge is relevant because treprostinil is a chemically synthesized small molecule.

What formulation patents may create generic entry risk?

The highest-risk claims for a competitor are those that combine:

• Treprostinil or treprostinil diolamine.
• An extended-release oral matrix.
• Specific release-rate parameters.
• A defined polymer or polymer concentration.
• A pulmonary arterial hypertension treatment method.
• A dose-escalation regimen tied to the product's pharmacokinetic profile.

A competitor may attempt a design-around using ethylcellulose, a different hypromellose grade, a multiparticulate system, an osmotic delivery platform, or a coated pellet formulation. The risk is that a different excipient system may produce unacceptable food effects, dose dumping, or a non-equivalent pharmacokinetic profile.

The most valuable formulation patent claims are those that capture performance rather than a narrow ingredient list. Claims based on dissolution windows, plasma exposure, reduced peak-to-trough fluctuation, or resistance to alcohol-induced release can be difficult to design around while preserving bioequivalence.

What commercial opportunities exist for excipient suppliers?

Controlled-release polymer supply

Hypromellose suppliers can compete for value through:

• Low- and high-viscosity grades.
• Tight substitution and viscosity specifications.
• Low bioburden and low endotoxin documentation where relevant.
• Consistent particle-size distribution.
• Regulatory support for global filings.
• Technical assistance with dissolution matching.

The strongest opportunity is long-term supply qualification for generic or reformulated treprostinil products. Once a modified-release formulation is locked, switching polymer grade can require substantial comparability work.

Excipient co-development

Excipient companies can offer formulation development packages that include:

• Design-of-experiments work on polymer concentration and tablet hardness.
• Blend-uniformity studies for low-dose API products.
• Dissolution method development.
• Fed and fasted performance assessment.
• Alcohol dose-dumping evaluation.
• Scale-up and process validation support.

This creates higher margins than simple excipient distribution and can make the supplier part of the customer's regulatory control strategy.

Alternative matrix technologies

Commercial opportunities exist for technologies that improve one or more of the following:

• Once- or twice-daily dosing.
• Food-effect control.
• Reduced gastrointestinal adverse effects.
• More predictable release at higher doses.
• Lower tablet burden during titration.
• Improved stability in humid climates.
• Easier manufacture across multiple strengths.

A successful alternative must demonstrate clinical and regulatory value. A formulation that merely replaces hypromellose with another polymer may not justify the cost of a 505(b)(2) program.

What manufacturing and intellectual-property barriers affect competition?

The main barriers are formulation reproducibility, analytical similarity, and patent clearance.

Treprostinil is administered at low doses but across a broad titration range. That increases the importance of:

• Uniform API distribution.
• Robust content uniformity.
• Controlled granule density.
• Consistent tablet hardness.
• Strength-to-strength proportionality.
• Stability across packaging configurations.
• Reliable dissolution at multiple pH conditions.

Packaging can also create a commercial opportunity. Moisture-barrier blister systems, desiccant-supported bottles, and unit-dose packaging may improve stability and adherence, although packaging changes must be supported by stability data and regulatory filings.

Geographic opportunity varies by jurisdiction. U.S. entry is governed by FDA approval and U.S. patent rights. Europe, Canada, Japan, and emerging markets apply separate patent, data-exclusivity, and regulatory rules. A formulation that is blocked by a U.S. patent may still be commercially viable in countries where the relevant patent was not granted or has expired.

How does Orenitram compare with other treprostinil products?

Product	Route	Commercial implication
Orenitram	Oral extended-release tablet	Competes on convenience and chronic outpatient administration
Remodulin	Subcutaneous or intravenous infusion	Requires pump-based delivery and creates administration burden
Tyvaso	Inhaled treprostinil	Uses inhalation equipment and different adherence considerations
Tyvaso DPI	Dry-powder inhaled treprostinil	Competes through device portability and administration convenience

Orenitram's excipient and patent strategy is therefore distinct from inhaled and injectable treprostinil products. The primary substitute is another oral modified-release product, not a conventional immediate-release tablet.

What is the revenue exposure from Orenitram competition?

Orenitram is one of United Therapeutics' commercial pulmonary hypertension products. Its value is linked to chronic treatment duration, dose escalation, and the company's ability to retain patients within its treprostinil franchise [3].

Generic entry could affect revenue through:

• Price erosion after the first approved competitor.
• Greater erosion after multiple ANDA approvals.
• Payer-driven substitution.
• Reduced ability to maintain premium pricing.
• Pressure on total treprostinil franchise revenue.

Revenue exposure depends on the timing of entry, number of competitors, settlement restrictions, and whether United Therapeutics introduces lifecycle-management products before generic launch. A formulation with a new dosing frequency, improved tolerability, or device-linked adherence could reduce substitution risk but would require clinical and regulatory investment.

Key Takeaways

• Orenitram is an oral extended-release treprostinil diolamine tablet approved by the FDA in 2013.
• Public labeling identifies hypromellose, lactose monohydrate, colloidal silicon dioxide, and magnesium stearate as core inactive ingredients.
• Hypromellose is the primary release-controlling excipient and the most important formulation variable for competitive development.
• Orenitram's NCE exclusivity period ended in 2018, but formulation and method-of-use patents may continue to affect generic entry.
• The Orange Book, not product labeling alone, determines the operative listed-patent and exclusivity position.
• The leading commercial opportunities are controlled-release polymer supply, excipient co-development, dissolution optimization, alternative matrix systems, and moisture-protective packaging.
• Biosimilar risk does not apply because treprostinil is a small-molecule drug.
• Generic competition is most likely to focus on extended-release performance, formulation patent design-arounds, and ANDA Paragraph IV strategy.

FAQs

Can a generic Orenitram use the same hypromellose excipient?

Yes. An ANDA applicant may use the same excipient if the formulation meets FDA requirements and does not infringe applicable patent claims. The applicant must control polymer grade, concentration, dissolution, and manufacturing conditions.

Is Orenitram an extended-release drug covered by the FDA Orange Book?

Yes. Orenitram is an FDA-approved extended-release tablet listed under a new drug application. The Orange Book should be used to identify current patents, use codes, and exclusivity information.

Could an osmotic tablet compete with Orenitram?

Potentially. An osmotic tablet could provide a design-around pathway, but it would need to demonstrate comparable exposure, acceptable food-effect behavior, dose proportionality, and a clinically acceptable safety profile.

Are treprostinil excipients subject to drug-specific FDA approval?

Excipients are not approved in the same manner as active ingredients. Their acceptability depends on route, dose, population, prior use, quality specifications, and the formulation's regulatory submission.

What is the strongest commercial position for an Orenitram excipient supplier?

The strongest position combines a qualified controlled-release polymer with formulation-development support, global regulatory documentation, supply continuity, and demonstrated performance across multiple tablet strengths.

References

1. U.S. Food and Drug Administration. (2013). Orenitram (treprostinil) extended-release tablets: Prescribing information. United Therapeutics Corporation. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203496s000lbl.pdf

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United Therapeutics Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=1082554

4. U.S. Food and Drug Administration. (n.d.). Regulatory exclusivity and patent information for approved drug products. https://www.fda.gov/drugs/development-resources/patent-and-exclusivity-information